JP7508375B2 - 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド - Google Patents

熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド Download PDF

Info

Publication number
JP7508375B2
JP7508375B2 JP2020564427A JP2020564427A JP7508375B2 JP 7508375 B2 JP7508375 B2 JP 7508375B2 JP 2020564427 A JP2020564427 A JP 2020564427A JP 2020564427 A JP2020564427 A JP 2020564427A JP 7508375 B2 JP7508375 B2 JP 7508375B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
groups
alkanediyl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524439A (ja
JPWO2019222269A5 (https=
JP2021524439A5 (https=
Inventor
シン チアン
メレアン ビスニック
クリストファー エフ． ベンダー
ゲイリー ボルトン
ブラッドリー カプレイズ
チタセ リー
Original Assignee
リアタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ インコーポレイテッド filed Critical リアタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021524439A publication Critical patent/JP2021524439A/ja
Publication of JPWO2019222269A5 publication Critical patent/JPWO2019222269A5/ja
Publication of JP2021524439A5 publication Critical patent/JP2021524439A5/ja
Priority to JP2024098452A priority Critical patent/JP2024125338A/ja
Application granted granted Critical
Publication of JP7508375B2 publication Critical patent/JP7508375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2020564427A 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド Active JP7508375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098452A JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
US62/671,047 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098452A Division JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Publications (4)

Publication Number Publication Date
JP2021524439A JP2021524439A (ja) 2021-09-13
JPWO2019222269A5 JPWO2019222269A5 (https=) 2022-05-20
JP2021524439A5 JP2021524439A5 (https=) 2022-05-20
JP7508375B2 true JP7508375B2 (ja) 2024-07-01

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564427A Active JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Country Status (18)

Country Link
US (2) US11827664B2 (https=)
EP (1) EP3794009A1 (https=)
JP (2) JP7508375B2 (https=)
KR (1) KR20210021457A (https=)
CN (2) CN119285591A (https=)
AU (2) AU2019271126B2 (https=)
BR (1) BR112020023277A2 (https=)
CA (1) CA3100333A1 (https=)
CL (1) CL2020002957A1 (https=)
CO (1) CO2020015380A2 (https=)
EA (1) EA202092727A1 (https=)
IL (2) IL278698B2 (https=)
MX (2) MX2020012366A (https=)
PE (1) PE20211917A1 (https=)
PH (1) PH12020551941A1 (https=)
SG (1) SG11202011311YA (https=)
UA (1) UA130486C2 (https=)
WO (1) WO2019222269A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900660T1 (it) 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114787139B (zh) 2019-11-26 2025-03-11 吉利德科学公司 用于制备mcl1抑制剂的方法和中间体
EP4247783A1 (en) 2020-11-19 2023-09-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506982A (ja) 2012-02-09 2015-03-05 ユニバーシティ・オブ・カンザス Ｃ末端Ｈｓｐ９０阻害剤
JP2017521496A (ja) 2014-06-24 2017-08-03 ザ ユニバーシティ オブ カンザス Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091171A1 (en) 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA2456281A1 (en) 2001-09-21 2003-04-03 Novartis Ag Pyrane derivatives as both ace- and nep- inhibitors
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008061108A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
JP5401329B2 (ja) 2007-03-20 2014-01-29 キュリス，インコーポレイテッド Ｈｓｐ９０インヒビターとしての縮合アミノピリジン
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
ES2475206T3 (es) 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
US20100022635A1 (en) 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
AU2014346483B2 (en) 2013-11-07 2019-01-17 The University Of Kansas Biphenylamide derivative Hsp90 inhibitors
CA2929243C (en) 2013-11-11 2022-05-03 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
CA2951270C (en) 2014-06-13 2023-07-04 The University Of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506982A (ja) 2012-02-09 2015-03-05 ユニバーシティ・オブ・カンザス Ｃ末端Ｈｓｐ９０阻害剤
JP2017521496A (ja) 2014-06-24 2017-08-03 ザ ユニバーシティ オブ カンザス Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANYIKA,M. et al.，Development of Noviomimetics as C-Terminal Hsp90 Inhibitors，ACS Medicinal Chemistry Letters，2016年，Vol.7, No.1，p.67-71
FORSBERG,L.K. et al.，Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects，European Journal of Medicinal Chemistry，2017年10月18日，Vol.143，p.1428-1435
Joseph A. BURLISON et al.，Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90，JOURNAL OF THE AMERICAN CHEMICAL SOCIETY，2006年，vol.128, no.48，p.15529-15536
Joseph A. BURLISON et al.，Synthesis and Evaluation of Coumermycin A1 Analogues that Inhibit the Hsp90 Protein Folding Machinery，ORGANIC LETTERS，2006年，vol.8, no.21，p.4855-4858
KUSUMA,B.R. et al.，Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity，Journal of Medicinal Chemistry，2012年，Vol.55, No.12，p.5797-5812
MA,J. et al.，Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons，ACS Chemical Neuroscience，2015年，Vol.6, No.9，p.1637-1648

Also Published As

Publication number Publication date
MX2020012366A (es) 2021-02-09
CN119285591A (zh) 2025-01-10
CO2020015380A2 (es) 2020-12-21
US20210261592A1 (en) 2021-08-26
IL278698A (https=) 2021-01-31
EP3794009A1 (en) 2021-03-24
UA130486C2 (uk) 2026-03-04
JP2021524439A (ja) 2021-09-13
AU2024267017A1 (en) 2024-12-19
SG11202011311YA (en) 2020-12-30
PH12020551941A1 (en) 2021-08-16
IL309891B1 (en) 2024-11-01
CA3100333A1 (en) 2019-11-21
IL309891A (en) 2024-03-01
US12595278B2 (en) 2026-04-07
IL278698B1 (en) 2024-02-01
KR20210021457A (ko) 2021-02-26
US20240182507A1 (en) 2024-06-06
AU2019271126B2 (en) 2024-08-29
BR112020023277A2 (pt) 2021-02-23
IL278698B2 (en) 2024-06-01
IL309891B2 (en) 2025-03-01
WO2019222269A1 (en) 2019-11-21
CL2020002957A1 (es) 2021-04-16
CN112513058A (zh) 2021-03-16
US11827664B2 (en) 2023-11-28
CN112513058B (zh) 2024-08-20
AU2019271126A1 (en) 2020-12-10
JP2024125338A (ja) 2024-09-18
MX2025007723A (es) 2025-08-01
PE20211917A1 (es) 2021-09-28
EA202092727A1 (ru) 2021-04-20

Similar Documents

Publication Publication Date Title
JP7508375B2 (ja) 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
AU2021202065B2 (en) Hepatitis B core protein modulators
TWI635083B (zh) １，４－雙取代嗒類似物及運動神經元存活（ｓｍｎ）缺乏相關病況之治療方式
CN102858767B (zh) 作为syk抑制剂的氨基嘧啶
TWI626247B (zh) 用於治療細菌感染之甘露糖衍生物
US12404266B2 (en) Heterocycle derivatives for treating TRPM3 mediated disorders
KR102057877B1 (ko) 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
RU2655914C9 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
WO2020135771A1 (zh) 杂环类化合物、中间体、其制备方法及应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN110248932B (zh) 用于抑制RORγ和其他用途的嘧啶三环烯酮衍生物
TW201920115A (zh) 化合物、組合物及方法
TW201920129A (zh) 化合物、組合物及方法
WO2018019297A1 (zh) 异喹啉酮类化合物及其制备抗病毒药物的应用
CN104592211A (zh) 联苯类化合物及其用途
CN111196804A (zh) TGF-βR1抑制剂及其应用
CN117794898A (zh) 3-吡咯基磺酰胺化合物作为gpr17拮抗剂
TW202246214A (zh) 蛋白磷酸酶 2a (pp2a) 的經取代環狀調節劑及使用其之方法
HK40046966A (en) Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
WO2024043334A1 (ja) 新規なピペラジン誘導体又はその塩及び医薬組成物
HK40046966B (zh) 治疗与热休克蛋白通路有关的疾病的具有修饰糖基团的联芳基酰胺类
TWI917480B (zh) 用於治療ｔｒｐｍ３介導病症之雜環衍生物
EA051397B1 (ru) Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока
HK40128865A (zh) 用於治疗中枢神经系统疾病或障碍的化合物
HK40048952B (zh) 杂环类化合物、中间体、其制备方法及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240619

R150 Certificate of patent or registration of utility model

Ref document number: 7508375

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150